Mycobacterium abscessus: A new antibiotic nightmare

Journal of Antimicrobial Chemotherapy

Volumn 67, Issue 4, 2012, Pages 810-818

  Nessar, Rachid ^a   Cambau, Emmanuelle ^a   Reyrat, Jean Marc ^a   Murray, Alan ^b,c   Gicquel, Brigitte ^b  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b INSTITUT PASTEUR   (France)

^c MASSEY UNIVERSITY   (New Zealand)

Author keywords

Acquired; Natural; Resistance

Indexed keywords

AMIKACIN; BEDAQUILINE; BETA LACTAM; CEFOXITIN; CIPROFLOXACIN; CLARITHROMYCIN; CLOFAZIMINE; DOXYCYCLINE; IMIPENEM; ISEPAMICIN; KANAMYCIN; LEVOFLOXACIN; LINEZOLID; MACROLIDE; MERCURY; MINOCYCLINE; MOXIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; SULFAMETHOXAZOLE; TETRACYCLINE; TIGECYCLINE; TOBRAMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL CELL; BACTERIAL MEMBRANE; BACTERIAL STRAIN; DRUG EFFICACY; GENETIC POLYMORPHISM; HUMAN; MYCOBACTERIOSIS; MYCOBACTERIUM ABSCESSUS; MYCOBACTERIUM ABSCESSUS SENSU STRICTO; MYCOBACTERIUM BOLLETII; MYCOBACTERIUM MASSILIENSE; NONHUMAN;

ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; MYCOBACTERIUM; MYCOBACTERIUM INFECTIONS;

EID: 84858638893     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkr578     Document Type: Article

References (98)

1. Moore M, Frerichs JB. An unusual acid-fast infection of the knee with subcutaneous, abscess-like lesions of the gluteal region; report of a case with a study of the organism, Mycobacterium abscessus, n. sp. J Invest Dermatol 1953; 20: 133-69.
2. Griffith DE, Aksamit T, Brown-Elliott BA et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007; 175: 367-416.
3. Esther CR Jr, Esserman DA, Gilligan P et al. Chronic Mycobacterium abscessus infection and lung function decline in cystic fibrosis. J Cyst Fibros 2010; 9: 117-23.
4. Griffith DE, Girard WM, Wallace RJ Jr. Clinical features of pulmonary disease caused by rapidly growing mycobacteria. An analysis of 154 patients. Am Rev Respir Dis 1993; 147: 1271-8.
5. Sermet-Gaudelus I, Le Bourgeois M, Pierre-Audigier C et al. Mycobacterium abscessus and children with cystic fibrosis. Emerg Infect Dis 2003; 9: 1587-91.
6. Radhakrishnan DK, Yau Y, Corey M et al. Non-tuberculous mycobacteria in children with cystic fibrosis: isolation, prevalence, and predictors. Pediatr Pulmonol 2009; 44: 1100-6.
7. Viana-Niero C, Lima KV, Lopes ML et al. Molecular characterization of Mycobacterium massiliense and Mycobacterium bolletii in isolates collected from outbreaks of infections after laparoscopic surgeries and cosmetic procedures. J Clin Microbiol 2008; 46: 850-5.
8. Koh SJ, Song T, Kang YA et al. An outbreak of skin and soft tissue infection caused by Mycobacterium abscessus following acupuncture. Clin Microbiol Infect 2010; 16: 895-901.
9. Leao SC, Tortoli E, Viana-Niero C et al. Characterization of mycobacteria from a major Brazilian outbreak suggests that revision of the taxonomic status of members of the Mycobacterium chelonae-M. abscessus group is needed. J Clin Microbiol 2009; 47: 2691-8.
10. Wallace RJ Jr, Brown BA, Griffith DE. Nosocomial outbreaks/pseudo-outbreaks caused by nontuberculous mycobacteria. Annu Rev Microbiol 1998; 52: 453-90.
11. Sanguinetti M, Ardito F, Fiscarelli E et al. Fatal pulmonary infection due to multidrug-resistant Mycobacterium abscessus in a patient with cystic fibrosis. J Clin Microbiol 2001; 39: 816-9.
12. Brown-Elliott BA, Wallace RJ Jr. Clinical and taxonomic status of pathogenic nonpigmented or late-pigmenting rapidly growing mycobacteria. Clin Microbiol Rev 2002; 15: 716-46.
13. Ripoll F, Pasek S, Schenowitz C et al. Non-mycobacterial virulence genes in the genome of the emerging pathogen Mycobacterium abscessus. PLoS One 2009; 4: e5660.
14. Adekambi T, Reynaud-Gaubert M, Greub G et al. Amoebal coculture of "Mycobacterium massiliense" sp. nov. from the sputum of a patient with hemoptoic pneumonia. J Clin Microbiol 2004; 42: 5493-501.
15. Zelazny AM, Root JM, Shea YR et al. Cohort study of molecular identification and typing of Mycobacterium abscessus, Mycobacterium massiliense, and Mycobacterium bolletii. J Clin Microbiol 2009; 47: 1985-95.
16. Macheras E, Roux AL, Ripoll F et al. Inaccuracy of single-target sequencing for discriminating species of the Mycobacterium abscessus group. J Clin Microbiol 2009; 47: 2596-600.
17. Bastian S, Veziris N, Roux AL et al. Assessment of clarithromycin susceptibility in strains belonging to the Mycobacterium abscessus group by erm(41) and rrl sequencing. Antimicrob Agents Chemother 2011; 55: 775-81.
18. Kim HY, Kim BJ, Kook Y et al. Mycobacterium massiliense is differentiated from Mycobacterium abscessus and Mycobacterium bolletii by erythromycin ribosome methyltransferase gene (erm) and clarithromycin susceptibility patterns. Microbiol Immunol 2010; 54: 347-53.
19. Ballarino GJ, Olivier KN, Claypool RJ et al. Pulmonary nontuberculous mycobacterial infections: antibiotic treatment and associated costs. Respir Med 2009; 103: 1448-55.
20. Jeon K, Kwon OJ, Lee NY et al. Antibiotic treatment of Mycobacterium abscessus lung disease: a retrospective analysis of 65 patients. Am J Respir Crit Care Med 2009; 180: 896-902.
21. Chopra S, Matsuyama K, Hutson C et al. Identification of antimicrobial activity among FDA-approved drugs for combating Mycobacterium abscessus and Mycobacterium chelonae. J Antimicrob Chemother 2011; 66: 1533-6.
22. Maxson S, Schutze G, Jacobs R. Mycobacterium abscessus osteomyelitis: treatment with clarithromycin. Infect Dis Clin Pract 1994; 3: 203-4.
23. Mushatt DM, Witzig RS. Successful treatment of Mycobacterium abscessus infections with multidrug regimens containing clarithromycin. Clin Infect Dis 1995; 20: 1441-2.
24. Lyu J, Jang HJ, Song JW et al. Outcomes in patients with Mycobacterium abscessus pulmonary disease treated with long-term injectable drugs. Respir Med 2011; 105: 781-7.
25. Jarlier V, Nikaido H. Permeability barrier to hydrophilic solutes in Mycobacterium chelonei. J Bacteriol 1990; 172: 1418-23.
26. Daffe M, Draper P. The envelope layers of mycobacteria with reference to their pathogenicity. Adv Microb Physiol 1998; 39: 131-203.
27. Brennan PJ, Nikaido H. The envelope of mycobacteria. Annu Rev Biochem 1995; 64: 29-63.
28. Trias J, Jarlier V, Benz R. Porins in the cell wall of mycobacteria. Science 1992; 258: 1479-81.
29. Nguyen L, Thompson CJ. Foundations of antibiotic resistance in bacterial physiology: the mycobacterial paradigm. Trends Microbiol 2006; 14: 304-12.
30. Alexander DC, Jones JR, Liu J. A rifampin-hypersensitive mutant reveals differences between strains of Mycobacterium smegmatis and presence of a novel transposon, IS1623. Antimicrob Agents Chemother 2003; 47: 3208-13.
31. Quan S, Venter H, Dabbs ER. Ribosylative inactivation of rifampin by Mycobacterium smegmatis is a principal contributor to its low susceptibility to this antibiotic. Antimicrob Agents Chemother 1997; 41: 2456-60.
32. Sha W, Weng XH, Xiao HP et al. [Investigation of drug-resistance to rifampin and rpoB gene sequence analysis of Mycobacterium abscessus]. Zhonghua Jie He He Hu Xi Za Zhi 2003; 26: 544-7.
33. Ainsa JA, Perez E, Pelicic V et al. Aminoglycoside 2'-N-acetyltransferase genes are universally present in mycobacteria: characterization of the aac(2')-Ic gene from Mycobacterium tuberculosis and the aac(2')-Id gene from Mycobacterium smegmatis. Mol Microbiol 1997; 24: 431-41.
34. Nurizzo D, Shewry SC, Perlin MH et al. The crystal structure of aminoglycoside-3'-phosphotransferase-IIa, an enzyme responsible for antibiotic resistance. J Mol Biol 2003; 327: 491-506.
35. Flores AR, Parsons LM, Pavelka MS Jr. Genetic analysis of the β-lactamases of Mycobacterium tuberculosis and Mycobacterium smegmatis and susceptibility to β-lactam antibiotics. Microbiology 2005; 151: 521-32.
36. Cook JL. Nontuberculous mycobacteria: opportunistic environmental pathogens for predisposed hosts. Br Med Bull 2010; 96: 45-59.
37. Nash KA, Brown-Elliott BA, Wallace RJ Jr. A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. Antimicrob Agents Chemother 2009; 53: 1367-76.
38. De Rossi E, Ainsa JA, Riccardi G. Role of mycobacterial efflux transporters in drug resistance: an unresolved question. FEMS Microbiol Rev 2006; 30: 36-52.
39. Louw GE, Warren RM, Gey van Pittius NC et al. A balancing act: efflux/influx in mycobacterial drug resistance. Antimicrob Agents Chemother 2009; 53: 3181-9.
40. Kerr ID. Structure and association of ATP-binding cassette transporter nucleotide-binding domains. Biochim Biophys Acta 2002; 1561: 47-64.
41. Kerr ID, Reynolds ED, Cove JH. ABC proteins and antibiotic drug resistance: is it all about transport? Biochem Soc Trans 2005; 33: 1000-2.
42. Domenech P, Reed MB, Barry CE III. Contribution of the Mycobacterium tuberculosis MmpL protein family to virulence and drug resistance. Infect Immun 2005; 73: 3492-501.
43. Goldberg M, Pribyl T, Juhnke S et al. Energetics and topology of CzcA, a cation/proton antiporter of the resistance-nodulation-cell division protein family. J Biol Chem 1999; 274: 26065-70.
44. Pasca MR, Guglierame P, De Rossi E et al. mmpL7 gene of Mycobacterium tuberculosis is responsible for isoniazid efflux in Mycobacterium smegmatis. Antimicrob Agents Chemother 2005; 49: 4775-7.
45. Ramon-Garcia S, Martin C, Thompson CJ et al. Role of the Mycobacterium tuberculosis P55 efflux pump in intrinsic drug resistance, oxidative stress responses, and growth. Antimicrob Agents Chemother 2009; 53: 3675-82.
46. Morris RP, Nguyen L, Gatfield J et al. Ancestral antibiotic resistance in Mycobacterium tuberculosis. Proc Natl Acad Sci USA 2005; 102: 12200-5.
47. Dubnau E, Chan J, Mohan VP et al. responses of Mycobacterium tuberculosis to growth in the mouse lung. Infect Immun 2005; 73: 3754-7.
48. Gomez JE, Bishai WR. whmD is an essential mycobacterial gene required for proper septation and cell division. Proc Natl Acad Sci USA 2000; 97: 8554-9.
49. Steyn AJ, Collins DM, Hondalus MK et al. Mycobacterium tuberculosis WhiB3 interacts with RpoV to affect host survival but is dispensable for in vivo growth. Proc Natl Acad Sci USA 2002; 99: 3147-52.
50. Davis NK, Chater KF. The Streptomyces coelicolor whiB gene encodes a small transcription factor-like protein dispensable for growth but essential for sporulation. Mol Gen Genet 1992; 232: 351-8.
51. Geiman DE, Raghunand TR, Agarwal N et al. Differential gene expression in response to exposure to antimycobacterial agents and other stress conditions among seven Mycobacterium tuberculosis whiB-like genes. Antimicrob Agents Chemother 2006; 50: 2836-41.
52. Betts JC, Lukey PT, Robb LC et al. Evaluation of a nutrient starvation model of Mycobacterium tuberculosis persistence by gene and protein expression profiling. Mol Microbiol 2002; 43: 717-31.
53. Rickman L, Scott C, Hunt DM et al. A member of the cAMP receptor protein family of transcription regulators in Mycobacterium tuberculosis is required for virulence in mice and controls transcription of the rpfA gene coding for a resuscitation promoting factor. Mol Microbiol 2005; 56: 1274-86.
54. Guillemin I, Jarlier V, Cambau E. Correlation between quinolone susceptibility patterns and sequences in the A and B subunits of DNA gyrase in mycobacteria. Antimicrob Agents Chemother 1998; 42: 2084-8.
55. Alcaide F, Pfyffer GE, Telenti A. Role of embB in natural and acquired resistance to ethambutol in mycobacteria. Antimicrob Agents Chemother 1997; 41: 2270-3.
56. Sreevatsan S, Stockbauer KE, Pan X et al. Ethambutol resistance in Mycobacterium tuberculosis: critical role of embB mutations. Antimicrob Agents Chemother 1997; 41: 1677-81.
57. Choi WS, Kim MJ, Park DW et al. Clarithromycin and amikacin vs. clarithromycin and moxifloxacin for the treatment of post-acupuncture cutaneous infections due to Mycobacterium abscessus: a prospective observational study. Clin Microbiol Infect 2011; 17: 1084-90.
58. Matrat S, Aubry A, Mayer C et al. Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones. Antimicrob Agents Chemother 2008; 52: 2909-14.
59. Barkay T, Miller SM, Summers AO. Bacterial mercury resistance from atoms to ecosystems. FEMS Microbiol Rev 2003; 27: 355-84.
60. Meissner PS, Falkinham JO III. Plasmid-encoded mercuric reductase in Mycobacterium scrofulaceum. J Bacteriol 1984; 157: 669-72.
61. Baulard A, Escuyer V, Haddad N et al. Mercury resistance as a selective marker for recombinant mycobacteria. Microbiology 1995; 141: 1045-50.
62. Martin C, Timm J, Rauzier J et al. Transposition of an antibiotic resistance element in mycobacteria. Nature 1990; 345: 739-43.
63. Musser JM. Antimicrobial agent resistance in mycobacteria: molecular genetic insights. Clin Microbiol Rev 1995; 8: 496-514.
64. Ramaswamy S, Musser JM. Molecular genetic basis of antimicrobial agent resistance in Mycobacterium tuberculosis: 1998 update. Tuber Lung Dis 1998; 79: 3-29.
65. Ramaswamy SV, Reich R, Dou SJ et al. Single nucleotide polymorphisms in genes associated with isoniazid resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother 2003; 47: 1241-50.
66. Sander P, Bottger EC. Mycobacteria: genetics of resistance and implications for treatment. Chemotherapy 1999; 45: 95-108.
67. Shakil S, Khan R, Zarrilli R et al. Aminoglycosides versus bacteria-a description of the action, resistance mechanism, and nosocomial battleground. J Biomed Sci 2008; 15: 5-14.
68. Prammananan T, Sander P, Brown BA et al. A single 16S ribosomal RNA substitution is responsible for resistance to amikacin and other 2-deoxystreptamine aminoglycosides in Mycobacterium abscessus and Mycobacterium chelonae. J Infect Dis 1998; 177: 1573-81.
69. Maus CE, Plikaytis BB, Shinnick TM. Molecular analysis of cross-resistance to capreomycin, kanamycin, amikacin, and viomycin in Mycobacterium tuberculosis. Antimicrob Agents Chemother 2005; 49: 3192-7.
70. Taniguchi H, Chang B, Abe C et al. Molecular analysis of kanamycin and viomycin resistance in Mycobacterium smegmatis by use of the conjugation system. J Bacteriol 1997; 179: 4795-801.
71. Suzuki Y, Katsukawa C, Tamaru A et al. Detection of kanamycin-resistant Mycobacterium tuberculosis by identifying mutations in the 16S rRNA gene. J Clin Microbiol 1998; 36: 1220-5.
72. De Stasio EA, Moazed D, Noller HF et al. Mutations in 16S ribosomal RNA disrupt antibiotic-RNA interactions. EMBO J 1989; 8: 1213-6.
73. Moazed D, Noller HF. Interaction of antibiotics with functional sites in 16S ribosomal RNA. Nature 1987; 327: 389-94.
74. Poehlsgaard J, Douthwaite S. Macrolide antibiotic interaction and resistance on the bacterial ribosome. Curr Opin Investig Drugs 2003; 4: 140-8.
75. Dautzenberg B, Truffot C, Legris S et al. Activity of clarithromycin against Mycobacterium avium infection in patients with the acquired immune deficiency syndrome. A controlled clinical trial. Am Rev Respir Dis 1991; 144: 564-9.
76. Leclercq R. Mechanisms of resistance to macrolides and lincosamides: nature of the resistance elements and their clinical implications. Clin Infect Dis 2002; 34: 482-92.
77. Brown BA, Wallace RJ Jr, Onyi GO et al. Activities of four macrolides, including clarithromycin, against Mycobacterium fortuitum, Mycobacterium chelonae, and M. chelonae-like organisms. Antimicrob Agents Chemother 1992; 36: 180-4.
78. Meier A, Kirschner P, Springer B et al. Identification of mutations in 23S rRNA gene of clarithromycin-resistant Mycobacterium intracellulare. Antimicrob Agents Chemother 1994; 38: 381-4.
79. Meier A, Heifets L, Wallace RJ Jr et al. Molecular mechanisms of clarithromycin resistance in Mycobacterium avium: observation of multiple 23S rDNA mutations in a clonal population. J Infect Dis 1996; 174: 354-60.
80. Nash KA, Inderlied CB. Genetic basis of macrolide resistance in Mycobacterium avium isolated from patients with disseminated disease. Antimicrob Agents Chemother 1995; 39: 2625-30.
81. Tebas P, Sultan F, Wallace RJ Jr et al. Rapid development of resistance to clarithromycin following monotherapy for disseminated Mycobacterium chelonae infection in a heart transplant patient. Clin Infect Dis 1995; 20: 443-4.
82. Wallace RJ Jr, Meier A, Brown BA et al. Genetic basis for clarithromycin resistance among isolates of Mycobacterium chelonae and Mycobacterium abscessus. Antimicrob Agents Chemother 1996; 40: 1676-81.
83. Macheras E, Roux AL, Bastian S et al. Multilocus sequence analysis and rpoB sequencing of Mycobacterium abscessus (sensu lato) strains. J Clin Microbiol 2011; 49: 491-9.
84. Adekambi T, Drancourt M. Mycobacterium bolletii respiratory infections. Emerg Infect Dis 2009; 15: 302-5.
85. Kim HY, Kook Y, Yun YJ et al. Proportions of Mycobacterium massiliense and Mycobacterium bolletii strains among Korean Mycobacterium chelonae-Mycobacterium abscessus group isolates. J Clin Microbiol 2008; 46: 3384-90.
86. Koh WJ, Jeon K, Lee NY et al. Clinical significance of differentiation of Mycobacterium massiliense from Mycobacterium abscessus. Am J Respir Crit Care Med 2011; 183: 405-10.
87. Monego F, Duarte RS, Biondo AW. gyrA and gyrB gene mutation in ciprofloxacin-resistant Mycobacterium massiliense clinical isolates from southern Brazil. Microb Drug Resist 2011; doi:10.1089/mdr.2011.0047.
88. Petrini B. Mycobacterium abscessus: an emerging rapid-growing potential pathogen. APMIS 2006; 114: 319-28.
89. Lee SM, Kim J, Jeong J et al. Evaluation of the brothmicrodilutionmethod using 2,3-diphenyl-5-thienyl-(2)-tetrazolium chloride for rapidly growing mycobacteria susceptibility testing. J Korean Med Sci 2007; 22: 784-90.
90. Park S, Kim S, Park EM et al. In vitro antimicrobial susceptibility of Mycobacterium abscessus in Korea. J Korean Med Sci 2008; 23: 49-52.
91. Miyasaka T, Kunishima H, Komatsu M et al. In vitro efficacy of imipenem in combination with six antimicrobial agents against Mycobacterium abscessus. Int J Antimicrob Agents 2007; 30: 255-8.
92. Wallace RJ Jr, Brown-Elliott BA, Crist CJ et al. Comparison of the in vitro activity of the glycylcycline tigecycline (formerly GAR-936) with those of tetracycline, minocycline, and doxycycline against isolates of nontuberculous mycobacteria. Antimicrob Agents Chemother 2002; 46: 3164-7.
93. Wallace RJ Jr, Brown-Elliott BA, Ward SC et al. Activities of linezolid against rapidly growing mycobacteria. Antimicrob Agents Chemother 2001; 45: 764-7.
94. Shen GH, Wu BD, Wu KM et al. In vitro activities of isepamicin, other aminoglycosides, and capreomycin against clinical isolates of rapidly growing mycobacteria in Taiwan. Antimicrob Agents Chemother 2007; 51: 1849-51.
95. Andries K, Verhasselt P, Guillemont J et al. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 2005; 307: 223-7.
96. Shen GH, Wu BD, Hu ST et al. High efficacy of clofazimine and its synergistic effect with amikacin against rapidly growing mycobacteria. Int J Antimicrob Agents 2010; 35: 400-4.
97. Woods GL, Bergmann JS, Witebsky FG et al. Multisite reproducibility of results obtained by the broth microdilution method for susceptibility testing of Mycobacterium abscessus, Mycobacterium chelonae, and Mycobacterium fortuitum. J Clin Microbiol 1999; 37: 1676-82.
98. Nessar R, Reyrat JM, Murray A et al. Genetic analysis of new 16S rRNA mutations conferring aminoglycoside resistance in Mycobacterium abscessus. J Antimicrob Chemother 2011; 66: 1719-24.